Skip to main
EXAS

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 13%
Hold 56%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences is positioned for significant growth, with expectations for Cologuard to increase its market share from approximately 15% to over 40%, driving substantial revenue growth. The company has recently raised its 2025 guidance following a strong Q3 performance, recording a 22% year-over-year growth in its core screening business, largely attributed to advancements in Cologuard rescreens and health plan initiatives. Furthermore, Exact Sciences is generating positive adjusted EBITDA and plans to screen at least 30 million people by 2027, representing a threefold increase in screenings, which bodes well for future financial performance.

Bears say

Exact Sciences is facing challenges due to its dependency on promotional marketing efforts to drive demand for its Cologuard screening test, which raises concerns about revenue stability. The company has a history of net losses, casting doubt on its ability to achieve and maintain GAAP profitability in the future. Furthermore, despite a projected revenue estimate of $4.0 billion for 2027, this figure is still below the company's targets, highlighting ongoing financial uncertainties and potential conservative assumptions in revenue projections.

Exact Sciences (EXAS) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 13% recommend Buy, 56% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 16 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.